How The BioXcel Therapeutics (BTAI) Story Is Shifting With BXCL501 Hopes And Dilution Risks [Yahoo! Finance]
BioXcel Therapeutics, Inc. (BTAI)
Last bioxcel therapeutics, inc. earnings: 11/14 07:00 am
Check Earnings Report
Company Research
Source: Yahoo! Finance
The key shift in the BioXcel Therapeutics story right now sits in the range of Street price targets, with one cut from US$10 to US$6 while other targets extend into the mid to high single digits and above, including US$10 and US$17. This spread reflects a clear divide between analysts who focus on the potential of the at home agitation and broader neuropsychiatry portfolio and those who put more weight on ongoing and expected equity dilution. As you read on, you will see how these moving targets shape the evolving narrative and what to watch next. Analyst Price Targets don't always capture the full story. Head over to our Company Report to find new ways to value BioXcel Therapeutics. What Wall Street Has Been Saying ?? Bullish Takeaways Rodman & Renshaw started coverage with a Buy rating and a US$17 price target, highlighting what it calls a differentiated at home agitation franchise and an expanding set of BXCL501 neuropsychiatry options. Rodman & Renshaw also points to wh
Show less
Read more
Impact Snapshot
Event Time:
BTAI
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BTAI alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BTAI alerts
High impacting BioXcel Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
BTAI
News
- BioXcel Therapeutics (BTAI) was downgraded by <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=BTAI&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street Zen</a> from "hMarketBeat
- BioXcel Therapeutics (BTAI) had its price target lowered by HC Wainwright from $6.00 to $5.00. They now have a "buy" rating on the stock.MarketBeat
- BioXcel Therapeutics Announces Food & Drug Administration Acceptance of Supplemental New Drug Application for Use of IGALMI® in the At-Home SettingGlobeNewswire
- Mosaic Therapeutics appoints Dr Vince O'Neill, MD, as Head of R&D [Yahoo! Finance]Yahoo! Finance
- BioXcel Therapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results as Company Prepares for Potential IGALMI® Approval in Outpatient Setting [Yahoo! Finance]Yahoo! Finance
BTAI
Earnings
- 11/12/25 - Miss
BTAI
Sec Filings
- 4/1/26 - Form 8-K
- 3/30/26 - Form SCHEDULE
- 3/27/26 - Form S-8
- BTAI's page on the SEC website